HY 2024 Results Presentation

Nick Sedgwick, CEO Andrew Franklin, CFO

30 September 2024

Contents

01

H1 2024

Overview

02

H1 2024

Results

03

FY 2024 Outlook

04

Key Brand Overview

05

100 Day Observations

06

Appendices

3

01

H1 2024

Overview

Andrew Franklin, CFO

4

H1 2024 Overview

On track to meet FY guidance

  • 5% CER growth in Group see-through revenues
  • Strong performance in Kelo-Cote on weak prior year comparator
  • Nizoral revenues declined, as expected, due to stocking cycles
  • Amberen revenues declined but remedial actions being implemented
  • Other Consumer Healthcare brands performed well
  • Prescription Medicines recovered due to full availability of stock
  • Gross margin expansion supporting increased investment in marketing and innovation
  • Robust free cash flow driving continued reduction in net debt

Group see through revenues (£84.8m)

Other

prescription

medicines

22%

Kelo-Cote

franchise

34%

Hydromol

6%

Other consumer

Amberen

brands

16%

MacuShield

Nizoral

6%

6%

10%

5

H1 2024 Overview

Positioning our business to deliver sustainable growth for the longer term

Brand developments

  • Continued progress from internal I&D
  • 6% of consumer health revenues from products launched in the last 3 years, up from 2% in H1 23
  • Three significant product launches in the period
    • Amberen Energy, Mood and Sleep gummy
    • MacuShield Omega 3
    • ScarAway Kids gel

Operational developments

  • ERP platform implemented in China
    • Completing the global roll-out of our single platform
  • Published our second TCFD report for 2023
  • Joined the UN Global Compact

6

02

H1 2024

Results

7

H1 2024 Results

Key financials

£84.8m

59.8%

£19.1m

See-through Revenue*

See-through Gross Margin*

Underlying EBITDA

£12.7m

1.80p

1.81x

Underlying Profit Before Tax

Underlying Basic EPS

Leverage

8

* Non-IFRS alternative performance measures. See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal.

For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

Revenue in more detail

Brand performance in H1 2024

Unaudited six months ended 30 June

2024

2023

Change

Growth

CER growth

£m

£m

£m

%

%

Kelo-Cote franchise

29.2

25.6

3.6

14%

18%

Nizoral*

8.3

11.1

-2.8

-25%

-21%

Amberen

5.2

5.9

-0.6

-11%

-9%

Other consumer brands

18.7

17.2

1.5

9%

9%

Consumer Healthcare

61.4

59.7

1.7

3%

6%

Prescription Medicines

23.3

22.7

0.6

3%

3%

See-through revenue*

84.8

82.4

2.3

3%

5%

H1

2023

H1

2024

Revenue distribution (H1 2024)

59.7

22.7

27%

61.4

23.3

73%

Consumer Healthcare

Prescription Medicines

Consumer Healthcare

Prescription Medicines

9

* Non-IFRS alternative performance measures. See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal.

For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

H1 2024 Results

Revenue and Underlying PBT development

Revenue movements (£m)

Underlying PBT movements (£m)

88.0

16.0

87.0

4.4

0.8

86.6

14.0

3.8

1.4

12.7

86.0

1.8

12.0

(2.3)

0.1

(0.3)

10.3

(0.4)

85.0

84.8

(1.8)

10.0

84.0

(2.3)

(0.5)

8.0

83.0

82.4

6.0

82.0

4.0

81.0

2.0

80.0

23

franchise

Nizoral

Amberen

Consumer

Prescription

CCY

Gain/(Loss)

Reported

-

Sales

H1

24

24

2023 H1 PBT

Operating Costs

Depr/Amort

Interest

H1

Gross Profit

Share Options

FX

2024 H1 PBT

Net

Kelo

- Cote

Other

Net

Sales

FX

Sales

H1

Net

10

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Alliance Pharma plc published this content on September 30, 2024 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on September 30, 2024 at 07:11:04 UTC.